The clinical trial investigates the efficacy of semaglutide, a GLP-1 receptor agonist, in patients with Type 2 Diabetes Mellitus (DMT2) and moderate to severe plaque psoriasis. Given the increasing prevalence of both DMT2 and psoriasis, successful outcomes could position semaglutide as a dual-action therapy, potentially expanding its market share beyond diabetes management into dermatological applications. This could enhance the competitive landscape against existing psoriasis treatments and other GLP-1 receptor agonists. The trial's completion in June 2024 may provide timely data for strategic positioning in the market, particularly as the psoriasis treatment sector continues to grow.